Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma.

Raphaele Teixeira MazzaroMahanna Vanzeler VazRebeka Caribé BadinEliza Dalla BernardinaLiliane Rosa Alves Manaças

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Even with granulocyte colony-stimulating factor prophylaxis, an overall prevalence of 2.15% of febrile neutropenia associated with hospitalization was observed, causing negative outcomes in chemotherapy treatment of patients.

Keyphrases

chemotherapy induced
soft tissue
peripheral blood
risk factors
recombinant human
squamous cell carcinoma
bone loss
radiation therapy
glycemic control
urinary tract infection